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ABSTRACT
The androgen receptor (AR) is a ligand-inducible
transcription factor that mediates androgen action
in target tissues. Upon ligand binding, the AR binds
to thousands of genomic loci and activates a
cell-type specific gene program. Prostate cancer
growth and progression depend on androgen-
induced AR signaling. Treatment of advanced
prostate cancer through medical or surgical castra-
tion leads to initial response and durable remission,
but resistance inevitably develops. In castration-
resistant prostate cancer (CRPC), AR activity
remains critical for tumor growth despite androgen
deprivation. Although previous studies have
focused on ligand-dependent AR signaling, in this
study we explore AR function under the androgen-
deprived conditions characteristic of CRPC. Our
data demonstrate that AR persistently occupies a
distinct set of genomic loci after androgen depriv-
ation in CRPC. These androgen-independent AR
occupied regions have constitutively open chroma-
tin structures that lack the canonical androgen
response element and are independent of FoxA1,
a transcription factor involved in ligand-dependent
AR targeting. Many AR binding events occur at
proximal promoters, which can act as enhancers
to augment transcriptional activities of other pro-
moters through DNA looping. We further show that
androgen-independent AR binding directs a
gene expression program in CRPC, which is neces-
sary for the growth of CRPC after androgen
withdrawal.
INTRODUCTION
One of the major challenges in the management of
prostate cancer is the treatment of patients who no
longer respond to androgen deprivation therapy.
Available treatments for androgen deprivation therapy re-
sistant patients have had modest success, with improve-
ments in survival measured in months (1–5). How prostate
cancer cells acquire the ability to survive and proliferate
after androgen deprivation is not fully understood.
Importantly, the failure of androgen deprivation therapy
is not accompanied by the loss of the androgen receptor
(AR) or AR activity, but rather with restoration of AR
activity through a variety of mechanisms including AR
ampliﬁcation and overexpression, AR mutation (mostly
in the ligand-binding domain, conferring ligand promiscu-
ity), increased intratumoral androgen synthesis, androgen-
independent AR activation by cytokines and growth
factors and constitutively active AR splice variants (6–11).
While mounting evidence shows that AR signaling is crit-
ical in both androgen-dependent prostate cancer (ADPC)
and castration-resistant prostate cancer (CRPC), import-
ant differences in AR-mediated transcription have been
observed. Gene expression proﬁling has shown that the
androgen-dependent AR expression program characteris-
tic of ADPC is signiﬁcantly attenuated in CRPC (12,13).
To understand how AR functions in ADPC and CRPC,
previous studies have mapped genome-wide androgen-
dependent AR-occupied regions in ADPC (such as
LNCaP cells) and CRPC (LNCaP-derived cells) cells
using chromatin immunoprecipitation (ChIP)-based
approaches (14–22). This approach has led to identiﬁcation
of CRPC-speciﬁc androgen-dependent AR binding events
associated with M-phase cell cycle genes (20), suggesting
that androgen-induced AR signaling is altered in CRPC
cells through reprogramming of androgen-induced AR
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binding. Androgen-induced AR reprogramming is also
observed after downregulation of FoxA1, a pioneer tran-
scription factor involved in AR targeting and frequently
mutated in prostate cancer (21,23,24), although the role
of FoxA1 in CRPC remains to be determined. Notably,
these studies have focused on AR binding events in
the presence of androgen [typically after 10 nM
5a-dihydrotestosterone (DHT) treatment], based on the
notion that CRPC growth depends on incomplete
androgen suppression and continuous ligand-dependent
activation of ampliﬁed or hypersensitive AR (6,25,26).
Whereas a ligand-dependent AR-mediated gene expres-
sion program may play an important role in CRPC,
ligand-independent activation of the AR is believed to
account for CRPC growth in a subset of patients.
Notably, upregulation of PI3K/AKT, MAPK and
HER2/neu signaling promotes androgen-independent
growth of prostate cancer in vitro and in vivo (27–29).
Androgen-independent AR DNA binding and transcrip-
tional activity can be induced through increased tyrosine
phosphorylation and elevated ubiquitination of AR
(30,31). Furthermore, expression of constitutively active
AR splice variants lacking the ligand-binding domain
occurs frequently in CRPC, and is associated with
earlier disease recurrence (32–35). Despite this evidence
of androgen-independent AR activation, a detailed study
of the existence and biological signiﬁcance of AR binding
events under the androgen-deprived conditions has not
been reported.
In this study, we used ChIP-sequencing (ChIP-seq) and
RNA-sequencing (RNA-seq) to characterize AR binding
events in both the presence and absence of androgen in the
well-established LNCaP/C4-2B cell culture model. This
model shares strong similarities with the clinical progres-
sion from androgen-dependence to castration-resistance
(36,37). We observed a signiﬁcant number of androgen-
independent AR binding events that differ substantially
from classic androgen-dependent occupancies in CRPC
C4-2B cells. In androgen-deprived conditions, the AR per-
sistently occupies a set of genomic loci with constitutively
open chromatin structures that lack the canonical
androgen response element (ARE) and are not directed
by FoxA1. We show that androgen-independent AR
binding events lead to a distinct gene expression
program and drive CRPC cell growth. Taken together
with previous studies, these results suggest that both
androgen-dependent and -independent AR expression
programs are important mechanisms for the survival and
growth of CRPC. The relative importance of these
two pathways likely depends on cancer stage and tumor
microenvironment. Activation of an alternative androgen-
independent AR signaling pathway provides one mech-
anism by which CRPC cells can survive and grow in
androgen-deprived conditions.
MATERIALS AND METHODS
Cell culture and materials
LNCaP and C4-2B cells were maintained in RPMI 1640
media with 5% fetal bovine serum (FBS) as previously
described (38). Antibodies and siRNA reagents used in
this study are listed in Supplementary File S1.
ChIP and ChIP-seq
LNCaP or C4-2B cells were cultured in phenol red-free
RPMI 1640 media supplemented with 5% charcoal-
stripped FBS (CSS) for 3 days. After treatment with
ethanol or DHT (10 nM) for additional 4 h (for LNCaP)
or 16 h (for C4-2B), ChIP experiments were performed as
described previously (15,39). For the ChIP after FoxA1
knockdown, C4-2B cells were transfected with FoxA1
siRNA (ﬁnal 15 nM) or non-target siRNA using
Lipofectamine RNAiMAX Transfection Reagent and
Reverse Transfection Protocol (Invitrogen), and then
grown in phenol red-free RPMI 1640 containing 5%
CSS for 3 days prior to ChIP. ChIP DNA was analyzed
by quantitative polymerase chain reaction (qPCR) using
TaqMan or SYBR PCR Master Mix (Applied
Biosystems). The primers and probes are listed in
Supplementary File S1.
The ChIP-seq libraries were prepared according to the
Illumina Protocol (www.illumina.com) with modiﬁca-
tions. Brieﬂy, 10 ng of ChIP DNA was end-repaired,
ligated to barcoded adaptors, size-selected on agarose
gel (300–500 bp) and PCR ampliﬁed for 16 cycles using
Phusion polymerase (Finnzymes). The libraries were
sequenced in the Illumina Genome Analyzer IIx or
HiSeq2000 system according to the manufacturer’s in-
struction. A summary of ChIP-seq experiments is
provided in Supplementary File S1.
ChIP-seq analysis
ChIP-seq reads were mapped to the human genome (hg18)
using Bowtie (40). Reads that did not map uniquely were
disregarded. SISSRS (41) was used to identify AR binding
sites, with input samples used as background and at a
P-value threshold of 0.01. DBChip was used to merge
sites identiﬁed by SISSRS into a list of AR binding sites
(±125 bp from the peak center) observed in at least one
experiment (42). Binding at a given AR site is reported in
counts per million (CPM) uniquely mapped reads. Peaks
mapping to ribosomal RNA (rRNA) or satellite repeats
[based on RepeatMasker 3.2.7 (43)] were disregarded since
they cannot be properly mapped due to incomplete anno-
tation. Binding sites with >1 CPM in C4-2B or LNCaP
input samples were also disregarded. Differentially bound
sites [false discovery rate (FDR)< 0.1] were identiﬁed
using edgeR (44) following previously described methods
(45). Tag-wise dispersion was modeled in edgeR using the
generalized linear model (glm) functionality, with
ChIP-seq antibody used as a blocking factor and normal-
ization based on the total number of uniquely mapped
reads. Genomic location of peaks was determined
relative to the nearest Ensembl transcript with a
complete annotation. The gene promoter was deﬁned as
±1kb relative to the transcription start site (TSS).
Transfer RNA (tRNA) annotations were based on
Repeat Masker and the GtRNAdb (46). In order to visu-
alize nucleosome depletion at AR bindings sites, 9 (0.13%)
androgen-dependent AR-occupied regions with outlying












histone H3 lysine 9 and 14 acetylation (AcH3) (maximum
signal> 0.5 cpm/bp) were removed when computing the
average AcH3 signal.
Motif ﬁnding
The MEME suite of analysis tools was used for motif
discovery and detection (47). De novo motif discovery
using MEME was performed within ±125 bp relative to
the ChIP-seq peak center using default MEME–ChIP
settings (48). AME was used to test for statistically signiﬁ-
cant over-representation of motifs (49). Known motifs
were obtained from the Jaspar core database (50).
siRNA transfection
C4-2B cells were grown in phenol red-free RPMI 1640
containing 5% CSS for 2 days. Cells were transfected
with siRNA duplexes as indicated at a ﬁnal concentration
of 15 nM using Lipofectamine RNAiMAX Transfection
Reagent and Forward (or Reverse) Transfection protocol
(Invitrogen). After transfection, cells were grown in
phenol red-free RPMI 1640 containing 5% CSS for 48 h
and then treated with ethanol or DHT (10 nM) for add-
itional 16 h. Total RNA extraction and protein extraction
were conducted for further assessment by RNA-seq, qRT–
PCR and western blot.
RNA-seq
RNA-seq was performed as reported previously with
modiﬁcations (51,52). Brieﬂy, 10 mg of total RNA was
oligo (dT) selected using the Dynabeads mRNA puriﬁca-
tion kit (Invitrogen) or depleted of rRNA using the
RiboMinus kit (Invitrogen) and subsequently fragmented
using RNA Fragmentation Reagents (Ambion). The frag-
mented RNA was randomly primed with hexamers and
reverse-transcribed using the Just cDNA Double-
stranded cDNA Synthesis kit (Stratagene). After
second-strand synthesis, the cDNA was end-repaired,
ligated to barcoded adaptors, size selected on agarose
gel (150–300 bp) and PCR ampliﬁed for 14 cycles using
Phusion polymerase (Finnzymes). The libraries were
sequenced in the Illumina Genome Analyzer IIx or
HiSeq2000 system according to the manufacturer’s in-
struction. A summary of the RNA-seq experiments is
provided in Supplementary File S1.
RNA-seq analysis
RNA-seq reads were mapped to the human genome
(hg18) using Tophat (53). Aligned reads were ﬁltered to
eliminate reads that mapped to rRNA and RNA repeats
(snRNA, scRNA, srpRNA, tRNA and RNA). Htseq-
count (54) was used to obtain raw read counts based on
Ensembl gene annotations (hg18 v54) using the union
method. Genes that mapped to ribosomal and mitochon-
drial proteins, or did not have at least 5 counts per million
(CPM> 5) uniquely mapped reads in at least two samples
were ﬁltered prior to differential testing. Ensembl genes
lacking a corresponding RefSeq mRNA entry were also
eliminated. Differentially expressed genes (FDR=0.05
and 1.5-fold change) were identiﬁed using edgeR (44)
with TMM normalization (55) and tag-wise dispersion.
Gene ontology analysis was performed using GOstats
(56) and MetaCore from GeneGo Inc. Gene set enrich-
ment analysis (57) was performed using the Bioconductor
package phenoTest (58), with curated gene signatures
obtained from the GeneSigDB (59). Gene expression is
reported in CPM or fragments per kilobase of exon per
million mapped reads (FPKM).
qRT–PCR
After the indicated treatments, total RNA from cells was
extracted using TRIzol Reagent (Invitrogen). cDNA was
prepared through reverse transcription (RT) using the
iScript cDNA Synthesis Kit (Bio-Rad), and qPCR was
conducted using SYBR Green PCR Master Mix
(Applied Biosystems). Triplicate PCR reactions were con-
ducted. glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA expression was analyzed for each
sample in parallel. The primers are listed in
Supplementary File S1.
Western blot analysis
Western blots were performed as previously described
using the indicated antibodies (60).
Construction of plasmids
In total, 10 androgen-dependent and 10 androgen-
independent AR-occupied regions were PCR ampliﬁed
from C4-2B genomic DNA and subcloned upstream of a
minimal promoter into pGL4.26 vector (Promega). Five
out of 10 androgen-independent AR-occupied regions are
located at the promoter regions, which were cloned in
reverse direction to minimize the promoter activity in
luciferase assays. Also, 10 random genomic regions were
subcloned into pGL4.26 vector and used as controls. The
plasmid sequences were conﬁrmed by Sanger sequencing.
The primers for cloning are listed in Supplementary
File S1.
Luciferase assay
LNCaP or C4-2B cells (4 104 cells/well) were plated in
48-well plates and grown in phenol red-free RPMI 1640
containing 5% CSS for 2 days. Cells were then transfected
with luciferase reporter plasmids (100 ng/well) using
Lipofectamine LTX Reagent (Invitrogen). pRL-TK
renilla luciferase plasmid (10 ng/well) (Promega) was
co-transfected as an internal control. For the luciferase
assay after AR knockdown, cells were transfected with
AR siRNA (ﬁnal 15 nM) using Lipofectamine
RNAiMAX Transfection Reagent and Reverse
Transfection Protocol (Invitrogen), and then grown in
phenol red-free RPMI 1640 containing 5% CSS for 2 days
prior to reporter plasmid transfection. After plasmid trans-
fection, cells were treated with ethanol or DHT (10 nM) for
24 h. Fireﬂy and renilla luciferase activities were measured
using the Dual-Glo Luciferase Assay System (Promega).
Results are represented as ﬁreﬂy/renilla ratio.












Cell proliferation and apoptosis assays
C4-2B cells (1 104 cells/well) were plated in 96-well
plates and transfected with gene-speciﬁc siRNA at a
ﬁnal concentration of 15 nM using Lipofectamine
RNAiMAX Transfection Reagent and Reverse
Transfection Protocol. For proliferation assay, cells were
maintained in phenol red-free RPMI 1640 containing 5%
CSS with ethanol or different concentrations of R1881 as
indicated for 5 days. The synthetic androgen R1881 was
used instead of DHT to minimize metabolic degradation
during incubation. The number of viable cells was
analyzed using the CCK-8 kit (Dojindo Molecular
Technologies). For apoptosis assay, cells were grown in
phenol red-free RPMI 1640 containing 5% CSS with
ethanol or DHT (10 nM) for 3 days after siRNA transfec-
tion. The Caspase 3/7 activity was measured using the
Caspase-Glo 3/7 Assay kit (Promega).
Chromatin conformation capture assay
Chromatin conformation capture (3C) assays were per-
formed as previously reported with modiﬁcations (61–
63). Brieﬂy, LNCaP or C4-2B cells (1 107 cells/150mm
dish) were grown in phenol red-free RPMI 1640 containing
5%CSS for 3 days. Cells were ﬁxed with 1% formaldehyde
for 10min at room temperature, and then lysed in cold lysis
buffer [10 mM Tris–HCl (pH 7.5), 10mM NaCl, 0.2%
Igepal CA-630, 1protease inhibitor cocktail (Roche)].
The nuclei were harvested and suspended in digestion
buffer containing 0.3% SDS and 2% Triton X-100. The
chromatin was digested with BamHI or EcoRI (New
England Biolabs) overnight at 37C while shaking at
900 rpm. The reaction was then diluted with ligation
buffer containing 0.1% SDS and 1% Triton X-100 in a
ﬁnal volume of 7ml. Ligation was incubated at 16C over-
night with 2000 U T4 DNA ligase (New England Biolabs),
followed by overnight incubation at 65C in the presence of
10 mg/ml proteinase K (Sigma) to reverse cross-linking. The
DNA was isolated by phenol–chloroform extraction and
ethanol precipitation. The puriﬁed DNA was quantiﬁed
and used as a PCR template.
To create a standard for normalization of different PCR
efﬁciencies, 3C control template was generated by digest-
ing an equimolar mix of the PCR fragments spanning all
restriction sites of interest followed by ligation to produce
all possible ligation products (62). To control for differ-
ences of the 3C efﬁciency in different samples, the inter-
action of two sites at the TUBG2 locus was utilized as an
internal control. TUBG2 is equally expressed in both cell
lines. The efﬁciency of chromatin digestion at BamHI and
EcoRI sites was >80% determined by qPCR amplifying a
fragment spanning a BamHI or EcoRI site in the uncut
and cut chromatin. A Taqman probe and a forward (or
reverse) primer were designed speciﬁcally to a BamHI or
EcoRI fragment at the AI-OR of interest. Multiple reverse
(or forward) primers were then designed, which were
speciﬁc to different BamHI or EcoRI fragments across
the whole region. All qPCR reactions were carried out
in duplicate and compared against standard curves of
3C control template. The interaction frequency of the
closest point to the AI-OR in C4-2B cells was deﬁned as
100. The results are presented as the mean±standard de-
viation of two independent 3C preparations. Sequences
for primers and probes are listed in Supplementary
File S1.
RESULTS
Identiﬁcation of androgen-independent AR binding events
in CRPC cells
The LNCaP cell line, which expresses a functional albeit
mutant AR, has a robust transcriptional response to
androgen (38) and depends on androgen for cell prolifer-
ation (Supplementary Figure S1A). C4-2B is a CRPC cell
line derived from a LNCaP xenograft that relapsed and
metastasized to bone after castration. C4-2B cells show
similar growth rates in the presence or absence of
androgen. In the presence of androgen, C4-2B cell
growth is inhibited by the AR antagonist bicalutamide,
indicating androgen-dependent AR signaling remains
functional (Supplementary Figure S1B and C). In the
absence of androgen, however, growth of the C4-2B cells
is minimally affected by bicalutamide but strongly in-
hibited by siRNA against AR (Supplementary Figure
S1D and E). These results suggest that C4-2B cells in
androgen-deprived conditions exhibit androgen-
independent but AR-dependent growth. To understand
how AR promotes C4-2B cell growth under androgen-
deprived conditions, we asked whether AR genomic
binding events in the absence of androgen are present
and comparable with classic androgen-dependent
binding events. We mapped AR binding sites in LNCaP
and C4-2B cells in the presence and absence of DHT
(10 nM) using ChIP-seq. We identiﬁed a total of 15 709
AR binding events in at least one sample at a P-value
threshold of 0.01 (Figure 1A). In line with previous
studies, a large number of DHT-dependent AR binding
sites are observed in both LNCaP and C4-2B cells
(16,20,22). Most remarkably, we identiﬁed a set of AR
binding events persistently present in C4-2B cells even
after androgen withdrawal. Differential binding analysis
(45) was used to identify AR occupied regions with stat-
istically signiﬁcant differential binding in C4-2B DHT
versus LNCaP DHT+ cells (FDR = 0.1). We refer to
the 7135 AR binding sites with statistically increased
binding in LNCaP DHT+ cells as androgen-dependent
occupied regions (AD-ORs), whereas we refer to the 896
sites with statistically increased binding in C4-2B DHT
cells as androgen-independent occupied regions (AI-ORs)
(AD-OR and AI-OR examples in Figure 1B and full list in
Supplementary File S2). Selected AD and AI-ORs were
validated by ChIP–qPCR and showed good agreement
with ChIP-seq data (Supplementary Figure S2). We
hypothesized that AI-ORs are responsible for the
castration-resistant, AR-dependent phenotype in C4-2B
cells.
We observed similar DHT-dependent occupancy of
AD-ORs in LNCaP and C4-2B cells (Figure 1C), suggest-
ing that the androgen-dependent AR-mediated expression
program remains largely intact in CRPC. The occupancy
of AI-ORs in C4-2B cells was globally unaffected by DHT














Figure 1. Androgen-independent AR binding in CRPC cells. (A) DHT dependence of AR ChIP-seq signal intensity in a ±2kb region around 15 709
AR binding sites observed in at least 1 ChIP-seq sample in LNCaP DHT, LNCaP DHT+ (two replicates), C4-2B DHT (three replicates) and
C4-2B DHT+ (two replicates). AR binding sites located within ±1kb of a TSS are marked in blue (promoter). AR binding sites showing increased
binding in LNCaP DHT+versus C4-2B DHT are marked with red (androgen-dependent occupied regions or AD-ORs), whereas AR binding sites
showing increased binding in C4-2B DHT versus LNCaP DHT+ are marked green (androgen-independent occupied regions or AI-ORs)
(B) Normalized ChIP-seq read counts at representative AD-ORs (left) and AI-ORs (right) (C) DHT dependence of average AR binding at
AD-ORs and AI-ORs in LNCaP and C4-2B cells. Average binding is shown in log2 CPM, normalized by the number of uniquely mapped reads
in the sample.












treatment, and in speciﬁc cases, decreased (Supplementary
Figure S2). Interestingly, we also observed weak occu-
pancy at AI-ORs in parental LNCaP cells (Figure 1A
and B), consistent with the hypothesis that C4-2B cells
are a selected subpopulation of LNCaP cells (64). We
observed a similar pattern of androgen-dependent and
androgen-independent AR occupancies in an additional
CRPC cell line (22RV1), implying that androgen-
independent AR binding is not limited to the C4-2B
model (Supplementary Figure S3). The 22RV1 line was
derived from a CWR22 xenograft that relapsed during
androgen ablation (65). This cell line abundantly expresses
a common AR splice variant, which lacks the ligand-
binding domain. This truncated protein is constitutively
active and frequently detected in CRPC tumors (32–34).
Although AR binding in 22RV1 cells is relatively weak
compared to C4-2B cells, both common and cell-type
speciﬁc AR binding events were observed. Whether
androgen-independent AR binding in 22RV1 cells is
attributable to the AR splice variant lacking the ligand-
binding domain remains to be determined.
AI-ORs possess distinct genomic features from AD-ORs
We next investigated the properties of 7135 AD-ORs and
896 AI-ORs in C4-2B cells. Whereas the vast majority of
AD-ORs are located at intergenic and intronic regions in
line with previous ﬁndings (15,19), 54% of AI-ORs are
at promoters, exons and tRNA genes (Figure 2A).
Notably, the AR-bound promoter regions were among
the strongest AI-ORs (Figure 1A), suggestive of a poten-
tial importance in androgen-independent gene regulation.
FoxA1 has been characterized as a pioneer factor
involved in chromatin remodeling and facilitation of
androgen-dependent AR recruitment. FoxA1 is critical
for activation of androgen-dependent transcription
(15,66), and downregulation triggers dramatic repro-
gramming of AR binding (21,23). We next investigated
whether FoxA1 plays a similar role in androgen-
independent AR binding. Motif analysis showed that
both canonical ARE and FoxA1 motifs are not enriched
at AI-ORs (Supplementary Figure S4). Although no

























































CT    1     2      3     4     5     6     7     8   






Figure 2. Genomic localization and FoxA1 independence of AR binding at AI-ORs. (A) Genomic localization of AD-ORs and AI-ORs. (B)
DHT-treated and -untreated FoxA1 ChIP-seq signals at AD-ORs and AI-ORs. (C) AR occupancies measured by ChIP–qPCR at seven selected
AD-ORs and eight AI-ORs after FoxA1 knockdown. AR occupancy at the negative control (CT) region was deﬁned as 1. Knockdown of FoxA1
does not affect AR expression as demonstrated by the western blot (inset). Non-target siRNA (siNT) was used as a control.












novel motif overrepresented at promoter AI-ORs
compared with unbound promoters with no known
match in the JASPAR (50), TRANSFAC (67) and
UNIPROBE (68) databases. As expected, tRNA A- and
B-box motifs are highly enriched at tRNA AI-ORs.
ChIP-seq analysis of genome-wide FoxA1 binding sites
in C4-2B cells further revealed that FoxA1 was located
at AD-ORs, but not at AI-ORs (Figure 2B and
Supplementary Figure S5). Pre-existing FoxA1 binding
at AD-ORs was substantially enhanced after DHT treat-
ment in line with previous studies (15), suggesting a role in
androgen-mediated transcription other than opening of
nucleosomes. We next examined AR occupancies at
AD-ORs and AI-ORs using ChIP–qPCR after FoxA1
knockdown. While AR binding at ﬁve out of seven
AD-ORs was diminished by knockdown of FoxA1 in
agreement with FoxA1-directed AR reprogramming
(21,23), all eight AR occupancies at AI-ORs remained un-
changed (Figure 2C). These results demonstrate that
AI-ORs are FoxA1-independent and distinct from
classic AD-ORs.
AI-ORs are preferentially located at genomic loci with
constitutively open chromatin structures
Since AI-ORs lack pre-existing FoxA1 binding, we next
asked whether AI-ORs have a unique FoxA1-independent
chromatin structure. Histone H3 lysine 9 and 14 acetyl-
ation (AcH3) is associated with both promoters and en-
hancers and frequently marks active AR enhancers
(15,69). Upon DHT stimulation, AcH3 signals decreased
at the central position of AD-ORs and increased in the
ﬂanking regions in both LNCaP and C4-2B cells (Figure
3A). This is indicative of DHT-dependent nucleosome re-
positioning, which is hypothesized to increase chromatin
accessibility and facilitate transcription factor recruitment
(70). Since chromatin modiﬁcation signals vary at differ-
ent genomic elements, we separated AI-ORs into three
categories (promoter, tRNA and other). AI-ORs at
AR-bound promoter sites (Figure 3B, top panel) showed
strong AcH3 and promoter-speciﬁc histone H3 lysine 4
trimethylation (H3K4me3) signals that were unaffected
by DHT. Instead, a well deﬁned nucleosome-free region
immediately upstream of the TSS was present before and
after DHT treatment (Figure 3B). AI-OR binding at pro-
moters most commonly occurred immediately upstream of
the TSS near this nucleosome-free region (Supplementary
Figure S6A). AR-bound promoters had high CpG (HCG)
content (Supplementary Figure S6B) and displayed
increased levels of AcH3 and H3K4me3 relative to
unbound HCG promoters. AI-ORs at tRNA genes
(Figure 3B, middle panel) had a similar chromatin struc-
ture to those at promoters, whereas other AI-ORs (Figure
3B, bottom panel) showed elevated AcH3 and H3K4me3
marks centered at the AR binding sites. The lack of a
bimodal distribution at the non-promoter/non-tRNA
AR binding sites may suggest a distinct nucleosome archi-
tecture similar to that of the ‘gained’ AR binding sites
observed after FoxA1 knockdown (21). Importantly,
these histone modiﬁcation marks are largely unaffected
by DHT treatment. Notably, LNCaP chromatin structure
at AI-ORs was similar to that in C4-2B cells (Figure 3B,
right). This indicates that whereas open chromatin struc-
tures may be required for androgen-independent AR
binding, C4-2B AI-OR binding is likely determined by
AR DNA binding capacity and AR co-factor activity.
The de novo promoter motif may also play a role in AR
recruitment to speciﬁc promoters. In agreement with
highly activated epigenetic states, genes associated with
AR-bound promoter and exons were expressed at a
higher level than unbound genes (Figure 3C).
Collectively, AI-ORs occur at locations with open chro-
matin structures such as HCG promoters associated with
highly expressed genes and other open chromatin regions.
The chromatin structure of these regions does not change
upon DHT treatment and is independent of FoxA1
binding. These data are consistent with a model where
in C4-2B cells a subset of genomic loci with pre-existing
accessible chromatin serve as anchoring sites for
androgen-independent binding of activated AR.
AI-ORs possess AR-dependent enhancer activity
in CRPC cells
We next sought to determine whether AI-ORs exhibited
enhancer activity. We examined 10 AD-ORs and 10
AI-ORs in the context of a minimal promoter upstream
of the luciferase gene in a transient transfection system.
Both AD-ORs and AI-ORs displayed weak basal
enhancer activity in LNCaP cells under
androgen-deprived conditions compared with randomly
selected genomic regions (Figure 4A). We observed
higher basal activity at AD-ORs in C4-2B cells
compared with that in LNCaP cells likely due to increased
sensitivity of C4-2B cells to residual androgens (38).
Conversely, remarkably elevated basal activity was
observed at AI-ORs in untreated C4-2B cells. As
expected, AD-ORs showed DHT-induced enhancer
activity in both cell lines (Figure 4B). DHT treatment
did not affect enhancer activity of AI-ORs in LNCaP
cells, with a fold induction (DHT+/DHT) of 1. In
contrast, addition of DHT signiﬁcantly inhibited
enhancer activity at AI-ORs in C4-2B cells. Because AR
binding at AI-ORs is not altered by DHT treatment, the
decreased enhancer activity is likely due to transcription
squelching caused by robust DHT-mediated transcription
competing for common AR co-factors. Knockdown of
AR resulted in a decrease of basal enhancer activity at 9
out of 10 AI-ORs in C4-2B cells, suggesting that increased
DHT-independent enhancer activity depends on AR
binding (Figure 4C). This AR-dependent but
DHT-independent enhancer activity suggests that
AI-ORs may be important regulators of gene expression
in the CRPC phenotype.
AI-ORs regulate a distinct set of distal genes independent
of androgen
In order to identify potential targets of AI-OR-mediated
gene expression, we next used RNA-seq to identify genes
regulated by AR in the presence or absence of DHT and
after AR RNA interference (Supplementary Figure S7A).
We identiﬁed 431 DHT-upregulated genes in C4-2B cells












(Figure 4D and full list in Supplementary File S2). In agree-
ment with previous studies (15,19,20), these genes were
strongly correlated with AD-ORs based on the proximity
of activated genes (Figure 4E). We also identiﬁed 837 genes
that were upregulated in the absence of DHT in C4-2B
compared with LNCaP cells and could potentially
account for androgen-independent growth of C4-2B cells.
These genes, which we refer to as ‘androgen-independent
(AI) upregulated genes’, were largely distinct from
DHT-upregulated genes (Figure 4D, genes listed in
Supplementary File S2). AI-upregulated genes showed
strong genome-wide correlation with AI-ORs but not
AD-ORs. Because genome-wide analysis identiﬁed a signiﬁ-
cant number of AI-ORs localized to promoters, we also
asked whether AI-OR binding at the proximal promoter
correlated with expression of the bound gene.
Surprisingly, genes with AI-ORs at the proximal
promoter did not show statistically signiﬁcant upregula-
tion in C4-2B DHT versus LNCaP DHT cells
(Supplementary Figure S8). These results suggest that pro-
moter bound AI-ORs do not regulate the proximal gene,
but instead, regulate gene expression through long-range
A C
B
Figure 3. AI-ORs are preferentially located at open chromatin. (A) DHT dependence of AcH3 at AD-ORs. Data are plotted as reads per base pair
per peak, normalized to the maximum average signal for each experiment. (B) (top) DHT dependence of AcH3 and H3K4me3 at 276 AI-OR bound
promoters. Data are plotted as reads per base pair per peak, normalized to the maximum average signal at unbound HCG promoters for each
experiment. Note that 284 AI-ORs mapped to 276 promoters because some promoters were bound by multiple AI-ORs; (middle) AcH3 and
H3K4me3 signal at 54 AI-OR bound and 578 unbound tRNA. AI-OR bound tRNA show a DHT-independent increase in AcH3 and H3K4me3
signal relative to unbound tRNA. Data are plotted as reads per base pair per peak, normalized to the maximum average signal at unbound tRNA
for each experiment. Genomic locations of tRNA genes and pseudo-genes were obtained from the Genomic tRNA Database (46). Note that 20
tRNA genes annotated in repeat masker 3.2.7 but not included in the tRNA database were excluded when calculating the average signal; (bottom)
AcH3 and H3K4me3 signal at 538 non-promoter and non-tRNA AI-ORs. Bound sites show a DHT-independent increase in signal relative to
baseline, deﬁned as the average signal in a region 2.5–5 kb away from the AI-OR center. (C) Comparison of expression levels between genes with
promoter-bound AI-ORs, exonic AI-ORs, HCG promoters and all genes. Empirical P-values were determined by calculating median FPKMs for 1 x
107 simulated trials.












interactions. The constitutively high expression and open
chromatin structure of AI-OR bound promoters likely
explains the absence of regulation of the proximal gene.
AI-upregulated genes have a signiﬁcantly increased
probability of downregulation after AR RNA interference
(Supplementary Figure S9A), providing further evi-
dence that AR regulates the expression of these genes.
Interestingly, AI-upregulated genes also have a signiﬁ-
cantly increased probability of downregulation after
DHT treatment (Supplementary Figure S9B), in line
with the reduced enhancer activity of AI-ORs observed
in luciferase assays (Figure 4B). Our data thus suggest
that a distinct androgen-independent AR regulated gene
expression program is active in CRPC cells and is
regulated by androgen-independent AR binding. Upon
induction of CRPC cells by androgen, this androgen-
independent expression program is downregulated and
the classic androgen-dependent expression program
predominates.
AI-ORs directly interact with AI-upregulated genes
We next sought to conﬁrm the physical interaction
between AI-ORs and the distal AI-upregulated genes
using the quantitative 3C assay. Our results suggest that
AR promoter binding does not regulate the proximal
gene, but rather exhibits distal enhancer function. Here,
we examined three AI-ORs, two of which were located at
promoters. For example, AR was strongly bound to the
promoter of the SYS1 gene in C4-2B cells in the absence
of DHT. SYS1 expression levels were similar between
LNCaP and C4-2B cells, and remained unchanged after
AR knockdown (Figure 5A), suggesting that direct regu-
lation of this gene by AR was unlikely. In contrast, an
AI-upregulated gene, secretory leukocyte peptidase
inhibitor (SLPI), is located 110 kb away from this
SYS1 ﬂanking AI-OR (Figure 5B) and is downregulated
by both AR knockdown and DHT treatment. We found
that the interaction frequency between the SYS1 and
SLPI promoters was signiﬁcantly increased, compared
with nearby regions (Figure 5C). Interestingly, the same
interaction was weakly evident in LNCaP cells, consistent
with the weak AR binding at AI-ORs observed in LNCaP
cells. A similar interaction was demonstrated between
another promoter AI-OR and AI-upregulated gene
SERPINH1 (Supplementary Figure S10A). AR-mediated
regulation of gene expression through promoter–promoter
interactions is consistent with the observation that pro-
moters can exhibit enhancer function and augment the
transcriptional activity of other promoters through
DNA looping (71). In addition, the interaction between
an intergenic AI-OR and nearest AI-upregulated gene




Figure 4. AI-ORs possess AR-dependent enhancer activity and correlate with AI-upregulated genes. (A) Luciferase reporter assays showing basal
enhancer activity of random regions (n=10), AD-ORs (n=10) and AI-ORs (n=10) in the absence of DHT. P-values were calculated based on
matched two-tailed Student’s t-test. (B) DHT-induced enhancer activity of the same regions. (C) Basal enhancer activity of AI-ORs after AR
knockdown. The data were normalized to non-speciﬁc siRNA. (D) RNA-seq Venn diagram showing overlap between genes upregulated in C4-2B
DHT versus LNCaP DHT (termed AI-upregulated) and C4-2B DHT+ versus C4-2B DHT (termed DHT-upregulated). (E, F) Percentage of
AI-up and -downregulated, DHT up- and downregulated and all genes within 100 kb of (E) AD-ORs and (F) AI-ORs. P-values were calculated
based on a hypergeometric test.












Figure S10B). These results provide direct evidence that
AI-ORs interact with the promoters of nearby genes that
exhibit increased expression in androgen-deprived CRPC
cells. Androgen-independent AR binding likely directly
contributes to the androgen-independent AR-regulated ex-
pression program found in CRPC.
AI-upregulated genes are required for CRPC growth
We next investigated whether AI-upregulated genes are
necessary for the survival and proliferation of CRPC
cells after androgen withdrawal. We selected 10 AI-
upregulated genes for functional analyses, all of which
have an androgen-independent AR binding site within
150 kb and are downregulated after AR knockdown.
Signiﬁcant inhibitory effects on C4-2B proliferation after
gene-speciﬁc RNA interference was observed in the
absence of or at low concentrations of androgen (0.1 nM
R1881), accompanied by a corresponding increase in
apoptosis as determined by caspase-3 and -7 activities
(Figure 6). Notably, the inhibition of C4-2B cell prolifer-
ation was gradually abrogated when the androgen
Figure 5. AI-upregulated genes are regulated by distal AI-ORs. (A) Real-time RT–PCR results showing expression of SLPI and SYS1 genes in
LNCaP and C4-2B cells. SLPI but not SYS1 was downregulated after AR knockdown. (B) Normalized ChIP-seq read counts in the region near the
AI-OR and the SYS1 promoter in LNCaP and C4-2B cells. (C) 3C assays showing the interaction between the AI-OR at the SYS1 promoter and the
SLPI gene promoter. The results are presented as the mean±standard deviation of two independent 3C preparations. Small black arrows represent
the primers and a short red line indicates the probe for 3C-qPCR.












concentration was increased, presumably due to reactiva-
tion of DHT-responsive genes and attenuation of the
AI-OR-regulated gene program. These results suggest
that androgen-dependent and -independent AR signaling
pathways can coexist, but the androgen-independent
pathway predominates in the androgen-deprived condi-
tions characteristic of CRPC.
AI-upregulated genes are enriched for cell cycle functions
and overexpressed in CRPC tumors
We next performed gene ontology and gene set enrichment
analysis (GSEA) (57) on DHT and AI-upregulated genes.
Whereas DHT-upregulated genes were associated with re-
sponses to endoplasmic reticulum stress and protein
folding, AI-upregulated genes were highly enriched for
cell cycle (M phase), cell proliferation and angiogenesis
functions (Figure 7A) as determined using GOstats (56).
Enrichment of cell cycle genes was conﬁrmed using an
additional analysis tool (MetaCore from GeneGo Inc.,
Supplementary Figure S11). Notably, AI-upregulated
genes involved in cell cycle showed a strong spatial correl-
ation with AI-ORs (Figure 7B). GSEA using a publicly
available prostate cancer data set [GSE3325 (72)] showed
that both AI-upregulated genes and AI-upregulated ‘cell
cycle phase’ genes are signiﬁcantly upregulated in meta-
static prostate tumors (Figure 7C). In addition, GSEA
analysis using a database of publicly available gene ex-
pression signatures (59) revealed that genes upregulated
in C4-2B DHT versus LNCaP DHT cells were
strongly associated with a signature of CRPC bone
metastases (73) (Figure 7D).
The enrichment of mitotic cell cycle genes is consistent
with previously reported ontology analysis of genes
upregulated in the LNCaP-abl model of CRPC (20). We
ﬁnd signiﬁcant similarity in gene expression and ontology
in the two CRPC models, with 36% of AI-upregulated
genes and 69% of AI-upregulated ‘cell cycle phase’
genes also upregulated in LNCaP-abl cells in the
absence of androgen (Supplementary Figure S12A), sug-
gesting that similar pathways are activated in response to
androgen-deprivation in different models of CRPC. It is
important to note, however, that upregulation of
LNCaP-abl genes was attributed to DHT-induced AR
occupancies, in contrast to the androgen-independent
occupancies identiﬁed here. Whereas we observed consid-
erable overlap of AD-ORs between C4-2B and LNCaP-
abl cells, AI-ORs were largely unique to C4-2B cells
(Supplementary Figure S12B). These results suggest that
the growth of CRPC can be driven by similar gene expres-
sion programs that can be upregulated through different
transcriptional mechanisms. These commonly upregulated
genes and pathways provide potential therapeutic targets
for CRPC treatments against both androgen-dependent
and androgen-independent AR signaling.
DISCUSSION
Given the importance of AR signaling in CRPC, there has
been a dedicated interest in dissecting the mechanisms of
AR function after androgen deprivation. Many lines of
evidence suggest that androgen-dependent AR signaling
remains functional in CRPC. It is known that the serum
in clinical CRPC is never totally androgen free, that
residual androgens are present within the prostate at
levels capable of activating the AR despite castration
and that enhanced intratumoral androgen synthesis
has been commonly observed in CRPC (25,26,74).
Furthermore, >50% of CRPC patients showing disease
progression on initial lines of hormonal therapies remain
responsive to further hormone manipulation (75), suggest-
ing that androgen-dependent AR function remains in
CRPC. As a result, AR activity in CRPC has been
assessed largely based on androgen-responsive reporters
or prostate speciﬁc androgen (PSA) production. Next-
generation drugs have targeted androgen-dependent AR
signaling by inhibition of androgen synthesis (abiraterone)
Figure 6. AI-upregulated genes are necessary for CRPC growth. (A) Heatmap showing inhibitory effects on C4-2B proliferation 5 days after
gene-speciﬁc siRNA transfection in different concentrations of R1881. Percentage inhibition is normalized to non-target siRNA. (B) Apoptosis
assay with C4-2B cells showing Caspase 3 and 7 activity 3 days after gene-speciﬁc siRNA transfection in the presence or absence of DHT (10 nM).
The results are presented as the mean± standard deviation of two independent experiments. *P< 0.05, two-tailed Student’s t-test.












and block of AR ligand-binding (MDV3100) (5,76,77).
However, the heterogeneous and often transient
response to these new anti-androgen therapies raises the
question of whether and how AR-mediated gene tran-
scription occurs in the absence of ligand binding.
Prostate cancer is a molecularly heterogeneous disease
even within a single patient, and multiple mechanisms may
co-ordinately contribute to CRPC progression. While
ligand-dependent AR signaling continues to play an im-
portant role in the early stages of CRPC when residual
androgen-mediated AR signaling is active, ligand-
independent activation of AR may occur in an envir-
onment where androgen levels are below castrate levels
following severe ligand-depriving therapies. Such
therapies have been associated with complete elimination
of testosterone in the tumor microenvironment (such as
bone) and in some cases a loss of CYP17 (a key enzyme in
androgen biosynthesis) in prostate cancer cells (78–80).
More importantly, the fact that all anti-androgen appr-
oaches eventually fail strongly demonstrates the need to
identify and target alternative androgen-independent AR
signaling pathways. We reason that androgen-dependent
and androgen-independent AR signaling can coexist, and
that the relative importance of these two pathways
depends on local androgen levels, AR expression and
other cellular contexts such as co-regulators (8,81). The
androgen-independent AR binding described here occurs
at extremely low levels of androgen, which may provide a
mechanism for CRPC to develop and survive in a truly
androgen-free milieu.
Previous studies have identiﬁed AR binding events
in the presence of androgen in CRPC cells (15,20,82,83).
In this study, we performed AR ChIP-seq in CRPC cells
cultured in hormone-depleted media and identiﬁed a large
number of robust androgen-independent AR binding
events. Taken together, these results show that both
androgen-dependent and -independent AR signaling play
a role in CRPC. The identiﬁcation of androgen-
independent AR binding events does not diminish the im-
portance of androgen-dependent AR signaling. In fact, the
androgen-dependent pathway is still intact in CRPC cells
and can be rapidly reactivated by androgen stimulation.
The fact that androgen-dependent CRPC growth can
be inhibited by blocking ligand binding using an AR an-
tagonist further supports the role of androgen-dependent
AR signaling in CRPC. In the absence of ligand, however,
the AR is no longer directed to canonical AD-ORs, but
persistently occupies genomic loci characterized by a
pre-existing accessible chromatin structure. These open
chromatin structures are often associated with constitu-
tively active genes whose expression is unaffected by AR
binding. Instead, AI-ORs interact with neighboring genes
and regulate their expression through DNA looping.




Figure 7. AI-upregulated genes are associated with mitotic cell cycle, proliferation and metastasis. (A) Top 10 ontologies enriched in AI-upregulated
and DHT-upregulated genes as determined by GOstats (56). P-values were calculated based on a hypergeometric test with Benjamini–Hochberg
correction. (B) Distance from the TSS to the nearest AI-OR for AI-upregulated ‘cell cycle phase’ genes, AI-upregulated genes and all genes.
Empirical P-values are based on computing the median distance to the nearest AI-OR for randomly selected gene sets using 108 trials. (C)
AI-upregulated (left) and AI-upregulated ‘cell cycle phase’ genes (right) are enriched in metastatic versus localized CRPC. Genes were ranked by
fold change in publicly available metastatic versus localized prostate cancer samples (GSE3325). Black lines denote the position of the AI-upregulated
genes within the ranked list. (D) A signature of androgen-independent bone metastases (73) is associated with increased expression in C4-2B DHT
versus LNCaP DHT cells based on gene set enrichment analysis (GSEA). Genes were ranked by fold change in C4-2B DHT versus LNCaP
DHT cells. Black lines denote position of genes in the androgen-independent bone metastases signature within the ranked list.












set of cell-cycle genes that can drive cancer cell prolifer-
ation after androgen depletion. Although androgen stimu-
lation does not diminish AR occupancies at AI-ORs,
expression of AI-OR-associated genes may decrease,
likely due to transcription squelching. Inhibition of
androgen-independent pathways is accompanied by acti-
vation of androgen-dependent pathways, enabling cancer
cell survival in the absence or presence of androgen.
Recent studies show that promoter–promoter inter-
actions are widespread in human cells (71,84), with
many chromatin complexes spanning 150–200 kb. Our
results suggest that AR-bound promoters interact with
distal genes through a similar promoter-centered inter-
action. The AR may function as a bridge between two
promoters and bring general transcription machinery
from a highly active promoter to a distal target gene. An
important question is how the AR is recruited to AI-ORs
independent of androgen stimulation. Previous studies
showed that AR protein is more active and stable in
LNCaP-derived CRPC cells (C4-2 or C4-2B cells)
compared with parental cells (38,85,86). AR in C4-2B
cells is also predominately localized to the nucleus, sug-
gestive of intrinsic transcriptional activity. There is a
growing body of evidence suggesting that the AR can be
activated through a range of post-translational modiﬁca-
tions (87), which may provide an explanation for higher
AR activity and ligand-independent DNA binding in
C4-2B cells.
We conclude that androgen-dependent and androgen-
independent AR signaling can coexist in CRPC, with their
relative importance dependent on AR activity and
androgen levels in tumor microenvironment. Androgen
deprivation results in a dramatic alteration of genome-
wide AR occupancies and reprogramming of AR-
mediated gene expression. The androgen-independent
AR signaling described here may be an important thera-
peutic target when androgen-deprivation therapy and
anti-androgen treatments fail. More importantly, these
results suggest a general mechanism whereby, hormone
deprivation reprograms genome-wide hormone receptor
binding and gene regulation.
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